Susan Hasty, Publisher
Table of Contents . . . April 24th, 2002
Non-Subscriber - Summaries OnlyRelated Areas: Other Issues in Immunotherapy Weekly | Other Publications
Escherichia Coli - MGH study identifies key immune system molecule
Allergy Medicine - Experimental treatment for hay fever is safe, effective, and fast
Asthma - New therapy may reverse asthmatic condition in mice
Rheumatoid Arthritis - Early intervention is important
Stem Cell Transplantation - Campath-1G transiently depletes host dendritic cells
Tuberculosis - Researchers identify immune response to TB infection
Acute Leukemia - Study finds that marrow transplantation using unrelated donors should be considered for children
Allergic Rhinitis - UCD study: Central vacuum use eases allergy suffering
Antibody Screening - Centocor, Inc., expands its research agreement with MorphoSys AG
Appointments - Leading immunologist joins the scientific advisory board
Arthritis - Group claims arthritis drug may cause liver damage
Asthma - U.S. rates may be declining
Cancer Therapy - Ricerca, LLC, obtains drug development rights to new gene target
Crohn Disease - Remicade granted priority review by FDA for long-term treatment of CD
Fungus Therapy - Antifungal treatment Vfend in approved in Europe
Immune Modulation Therapies - Vasogen clinical trial identifies optimal treatment schedule in psoriasis
Immune System Deficiencies - Patent provides broad rights for Xcyte's core T cell therapy technology
Induction Therapy - Comparative study closed early because significantly fewer kidney rejections seen with Thymoglobulin
Multiple Sclerosis - UT Southwestern researchers discover how common MS drug slows progression of the disease
Psoriasis - Results of phase II clinical trial of Zenapax released
Rheumatoid Arthritis - Phase I clinical trial completed for AGIX-4207
Therapy - Widely used arthritis pills may be new treatment for cancer
Venous Thromboembolism - Study to evaluate Lovenox in patients with restricted mobility
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.